Between August 2017 and August 2018, 72 MRI-stratified patients with high-risk rectal cancer (cT3c/3d/T4a/T4b, cN2, MRF+, or EMVI+ disease) were enrolled in this study (Figure 1). The gene discussed is MYRF; the disease is rectal cancer.